文献速递炎症性肠病

英夫利西单抗与戈利木单抗治疗溃疡性结肠炎的疗效与起效速度比较

Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-05-18

本研究利用ACT-1、ACT-2和PURSUIT-SC三项3期试验的患者个体数据,比较标准剂量英夫利西单抗与戈利木单抗诱导治疗中重度溃疡性结肠炎的疗效与起效速度。英夫利西单抗在第2周和第6周达到患者报告结局2缓解的比例均显著高于戈利木单抗,诱导临床缓解的疗效也更强。

要点

  • 英夫利西单抗第2周患者报告结局2缓解率35% vs 戈利木单抗30%(校正OR 1.71,95%CI 1.15-2.55)
  • 第6周患者报告结局2缓解率英夫利西单抗50.0% vs 戈利木单抗38.9%(校正OR 2.0,95%CI 1.40-2.94)
  • 英夫利西单抗诱导临床缓解优于戈利木单抗(校正OR 3.01,95%CI 1.95-4.70)

核心结论

  • 基于3期试验患者个体数据分析,英夫利西单抗较戈利木单抗更快缓解中重度溃疡性结肠炎症状,且诱导缓解的疗效更强。

研究设计与样本

  • 采用3期试验(ACT-1、ACT-2和PURSUIT-SC)患者个体数据,比较标准剂量英夫利西单抗与戈利木单抗的疗效与起效速度。
  • 使用logistic广义估计方程比较第2周和第6周患者报告结局2缓解(直肠出血评分=0且排便频率评分≤1)的比例差异。
  • 使用logistic回归比较诱导临床缓解(Mayo评分<3)的总体疗效,并校正性别、病变范围、基线临床与内镜严重度、C反应蛋白、白蛋白、体重及合并用药(免疫抑制剂、糖皮质激素和5-氨基水杨酸)。

主要发现

  • 英夫利西单抗组第2周达到患者报告结局2缓解的比例为35%,戈利木单抗组为30%(校正OR 1.71,95%CI 1.15-2.55)。
  • 英夫利西单抗组第6周达到患者报告结局2缓解的比例为50.0%,戈利木单抗组为38.9%(校正OR 2.0,95%CI 1.40-2.94)。
  • 英夫利西单抗组达到临床缓解的可能性显著高于戈利木单抗组(校正OR 3.01,95%CI 1.95-4.70),在中度或重度溃疡性结肠炎患者中结果一致。
  • 各试验人群相似,各研究安慰剂组间未观察到差异。

关键数值与推荐

  • 患者报告结局2缓解定义为直肠出血评分=0且排便频率评分≤1。
  • 临床缓解定义为Mayo评分<3。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: With several options available for patients with moderate-severe ulcerative colitis (UC), rapidity of symptom resolution could be an important differentiator. We compared the efficacy and speed of onset of action of infliximab vs golimumab induction therapy using patient-level data from phase 3 trials (ACT-1, ACT-2, and PURSUIT-SC). METHODS: We compared differences in proportions of patients who achieved the composite outcome of a rectal bleeding score=0 and stool frequency score ≤1 (patient-reported outcome 2 remission) at weeks 2 and 6 of treatment with standard-dose infliximab vs golimumab using logistic generalized estimating equation. Overall efficacy for inducing clinical remission (Mayo clinic score <3) was compared using logistic regression. Analyses were adjusted for sex, disease extent, baseline clinical and endoscopic severity, C-reactive protein, albumin, body weight and concomitant medications (immunomosuppressives, corticosteroids, and 5-aminsalicylates). RESULTS: Trial populations were similar and no differences were observed among the placebo groups in the studies. A significantly higher proportion patients treated with infliximab than golimumab achieved patient-reported outcome 2 remission at week 2 (35% vs 30%; adjusted odds ratio [OR], 1.71; 95% CI, 1.15-2.55) and at week 6 (50.0% vs 38.9%; adjusted OR, 2.0; 95% CI, 1.40-2.94). Infliximab-treated patients were also significantly more likely to achieve clinical remission than golimumab-treated patients (adjusted OR, 3.01; 95% CI, 1.95-4.70), with consistent findings in patients with moderate or severe UC. CONCLUSIONS: Based on a patient-level analysis of data from phase 3 trials, infliximab resolves symptoms more rapidly and has greater efficacy for inducing remission than golimumab in patients with moderate-to-severe UC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Singh S, Proudfoot JA, Dulai PS, et al. Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019. PMID: 31108227. doi:10.1016/j.cgh.2019.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。